Technetium
As of the edition of 20 October 2026, Technetium is a small molecule: marketed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Small molecule
- Brand name
- Ultra-Technekow
- Approvals on record
- 21 in 21 regions
- Holder of the most recent approval
- Curium; 2 holders in all
- Registered trials
- 6, 1 stopped early
- Disease areas
- Cancer; Digestive system; Skin and connective tissue; Blood and lymph; Ear, nose and throat; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 3 | 2 | 1 | 0 | 1 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Cyclomedica | Lead sponsor of trials | 2017 to now |
| Btg | Lead sponsor of trials | 2023 to now |